Experience with Biobrane™; uses and caveats for success

Greenwood JE, Clausen J & Kavanagh S

Abstract

Objective
To present some of our experience with Biobrane™ (a total of 703 patients in 7 years) in a range of uses in burn practice and to illustrate the caveats which we have found applicable in maintaining our success with this versatile material.

Methods
Retrospective analysis of theatre records, medical notes and photography database to categorise our experience with Biobrane™. Thorough assessment of our surgical and nursing protocols (both literature and experience influenced) to identify caveats for successful use.

Results
Pivotal steps are revealed in wound selection, wound preparation, material application, dressing and subsequent nursing care which have led to overwhelming success in definitive management of superficial partial to mid-dermal burns (ensuring pain relief, allowing early mobilisation, tolerance of dressing changes and therapy, and earlier hospital discharge). Its many uses in a broad range of common burn situations are demonstrated and tips provided to achieve best outcome.

Conclusions
Biobrane™ is not a panacea but it is extremely versatile. The different potential uses have learning curves and suggestions are provided to flatten these.

Introduction
Biobrane™ was first introduced for the treatment of burn wounds and donor sites in 1979 1. It is a biosynthetic semi-permeable membrane designed to temporarily perform the functions of lost epidermis until re-epithelialisation. It is bilaminate material (Figure 1), consisting of a woven non-biodegradable nylon mesh; the superficial (outer) surface of which has a silastic coating (a mechanical barrier to vapour loss and bacterial ingress). Peptides derived from porcine type I collagen are bonded to all exposed nylon and silicone surfaces. The material bonds firmly to the adequately prepared bed of an appropriate burn (superficial partial to mid-dermal injury) until spontaneous detachment by re-epithelialisation. It is a lightweight material; being packaged and stored as dry sheets or gloves and has a long shelf-life. Our experience with Biobrane™ (a total of 703 patients in 7 years) reveals many other applications in burns practice, with some patients receiving Biobrane™ for more than one application.

Uses of Biobrane™
‘Standard’ Biobrane™ (15/3 denier nylon fibres) has been used exclusively for the following applications. The number in parentheses represents the number of cases in which Biobrane™ has been used for each application:
Definitive Treatment (Figure 2)

Failure of Biobrane™, when it is used for the definitive treatment of superficial partial thickness to mid-dermal burns, is rare in my practice. Success, however, is governed by a number of caveats that I have found to be unbreakable. Loss of Biobrane™ is chiefly due to non-adherence followed by infection. It cannot be used as definitive treatment in deeper (non-exuding) burns - these require excision and split skin grafting. The primary caveat, therefore, is burn selection. Obvious exudation, or the presence of blisters (popped or intact), indicate an intact sub-dermal circulation (Figure 2a). An exuding wound bed often cannot be fully appraised without the second caveat - meticulous wound cleaning and preparation (Figure 2b). This has seldom been possible without general anaesthesia since it involves aggressive cleaning to remove blister roofs/fragments, other non-viable tissue and surface contaminants such as dirt and soot. This process also reduces surface contamination by organisms which might have populated the wound during the ‘cooling’ process (clean running water not always available) or during the burning process (wound infection seems more common in burns caused by ‘organic’ agents such as cooking oils, stocks and water, sauces, petrol etc.). Following cleaning, the burn wound and an area of surrounding unburned skin (up to 10cm from the burn edge) is shaved of hair. Hair might ‘lay down’ during dressing application, but springs up later - the dressing detaches, air pockets develop which encourage bacterial ingress. Burns involving hands or feet need nail trimming and scrubbing to reduce these as a source of bacteria. These preparatory stages occur before ‘scrubbing up’. After full surgical scrub, the skin is prepared with full-strength Betadine™ and sterile drapes are applied around the surgical field. Residual Betadine™ is washed off with saline - it can be an irritant under Biobrane™, especially at the unburned margin. Tincture of Benzoin applied around the burn helps both Biobrane™ and adhesive tapes to adhere. Biobrane™ is applied (silastic shiny side out) and anchored at one margin with a 4cm wide strip of sterile Hypafix™. The opposite side is then similarly anchored under slight tension to eradicate any wrinkling of the Biobrane™. The other two sides are then anchored - it is useful to pick up the edge of the Biobrane™ with the tape which can then be pulled outward, affording required tension and ensuring excellent apposition of Biobrane™ and burn. On the limbs, Biobrane™ overdressed with full-strength Betadine™-soaked Nufold gauze dries out, becoming stiff, uncomfortable and resistant to movement/exercise. Weak (1 in 10) Betadine™ (100mls Betadine™ made up to 1L with sterile 0.9% saline), remains soft and conforming. To reduce dressing bulk, the gauze is held on directly with crêpe bandage, reducing heat and moisture at the wound site and limiting maceration. On the trunk, Biobrane™ is over-dressed with full-strength Betadine™-soaked Nufold gauze and anchored at one margin with a 4cm wide strip of sterile Hypafix™. The opposite side is then similarly anchored under slight tension to eradicate any wrinkling of the Biobrane™. The other two sides are then anchored - it is useful to pick up the edge of the Biobrane™ with the tape which can then be pulled outward, affording required tension and ensuring excellent apposition of Biobrane™ and burn. On the limbs, Biobrane™ overdressed with full-strength Betadine™-soaked Nufold gauze dries out, becoming stiff, uncomfortable and resistant to movement/exercise. Weak (1 in 10) Betadine™ (100mls Betadine™ made up to 1L with sterile 0.9% saline), remains soft and conforming. To reduce dressing bulk, the gauze is held on directly with crêpe bandage, reducing heat and moisture at the wound site and limiting maceration. On the trunk, Biobrane™ is over-dressed with full-strength Betadine™ and Hypafix™ - the treated back lies on an Exudry™ whilst the treated front is covered by Cutilin™. Post-operatively the treated part is elevated. Outer dressings are replaced daily. Certain structures should not be covered with Biobrane™, the nipples and the umbilicus in particular. A hole is cut out of the Biobrane™ to allow these structures to be externalised. Betadine ointment is applied to reduce their potential as
bacterial sources. The Biobrane™ glove has reduced surgical time after preparation for hand burns from 30-40 minutes each down to 5-10 minutes each (Figure 2c). The fingers are wrapped individually, the palm bolstered and a ‘boxing glove’ created (with MCPJs, PIPs and DIPS in flexion) with a crêpe bandage. This maximally stretches the dorsal hand burns in the knowledge that it is easier to regain finger extension than finger flexion (Figure 2d).

'Trial of Life'

Even after meticulous preparation, some burns appear to sit on the boundary between mid- and deep dermal; sometimes the boundary itself is indistinct. These burns sluggishly refill and the exudation from them is minimal; but if they might be even slightly capable of healing spontaneously, they receive Biobrane™ as a ‘Trial of Life’. Preparation of the burn wound is exactly the same as for definitive treatment, but the patient is counselled that success is not guaranteed and excision and grafting may be required if the Biobrane™ fails over the deeper areas.

Graft reduction (Figure 3)

In certain circumstances, a heterogeneous burn with an equivocal edge to the deeper areas receives Biobrane™, according to definitive treatment protocols (Figure 3a). In these cases, there is no doubt that these areas need to be excised and grafted but Biobrane™ is applied to allow the more superficial burns around them to heal and the edge to demarcate clearly. At excision, only non-viable tissue is excised and the least amount of graft possible is necessary (Figures 3b & 3c).

Salvage in the elderly (Figure 4)

The progressive thinning of the dermis and reduction in the density of adnexal structures in the elderly does not enable accurate prediction of spontaneous healing in burns which initially appear to be superficial partial thickness/mid-dermal in depth. This fact often catches out primary care givers who treat with SSD or Acticoat™ and discover, at review a few days later, that the burn has deepened; necessitating excision and grafting. Biobrane™ applied within 24 hours of the injury (and usually within a couple of hours of immediate post-burn admission) can salvage these burns (Figures 4a & 4b). Whether due to decontamination and preparation of the burn, or the application of Biobrane™, this procedure is more frequently successful than not (Figures 4c & 4d). Since the elderly cope poorly with a split-skin graft donor site (both in terms of healing and mobilisation), this salvage considerably reduces the morbidity of their injury. Failure is usually obvious within 3 days and definitive excision and grafting can then be performed.

Autograft holding in difficult sites

In major burn injury > 50% Total Body Surface Area (TBSA), where the back is involved and the patient initially managed on the Intensive Care Unit (ICU), ‘shear’ caused problems with split skin grafts on the back (despite Therakair™ mattresses). Shear often resulted from pulling the patient up the bed when being nursed at 30 - 45° to reduce facial swelling. When Biobrane™ is applied over meshed split skin graft, it adheres firmly to the interstices; effectively ‘spot-welding’ it into place (Figure 7d). Acticoat™ and Exudry™ outer dressings are applied and the Biobrane™ is examined daily. The graft is normally well taken by day 7 when SSD cream is applied (which loosens the fibrous clots holding the Biobrane™) and the material can be removed easily on day 8. This process does not appear to delay healing of the interstices at all. Biobrane™ also markedly assists in the holding of widely-meshed skin grafts over vascularised Integra™ during the serial delamination/grafting cycle in major burn injury.

Autograft holding in deep areas surrounded by superficial burn (Figure 5)
In cases of heterogeneous burns where the burn requiring excision is well demarcated immediately (Figure 5a), the deeper areas are excised and grafted (Figure 5b). If these areas are within a patch of superficial burn, Biobrane™ is applied over the whole wound (Figure 5c). The superficial burn is thus definitively treated by the Biobrane™ and the graft is firmly held in place. When the superficial areas are clinically healed (usually by day 9 or 10), SSD cream is applied as for ‘graft holding in difficult sites’.

**Post-dermabrasion dressing (Figure 6)**

When dermabrasion has been used for burn scar contour correction or re-pigmentation of burn hypopigmentation (Figures 6a & 6b), Biobrane™ is often an excellent dressing option, since the dermabraded bed is effectively a superficial partial thickness/mid-dermal wound. This option is only possible if a haemostatic tumescent technique has been employed to facilitate the surgery. In my experience, Biobrane™ applied to a bleeding bed is held by dense blood clot rather than fine fibrous clot and its subsequent detachment and removal is much more difficult.

**Retention of cell suspensions**

When cultured keratinocyte suspensions are applied over meshed split skin graft in our patients with burns >50% TBSA, Biobrane™ is the retention dressing of choice (Figure 7d). Despite the 1mm pores present in the film, the silastic layer generally minimises cell/media loss. This appears to be more effective than other commonly used materials, such as Surfasoft™.

**Temporising dressing post-burn excision (Figure 7)**

The tumescent technique we employ enables the complete excision of all burn eschar (even in >80% TBSA burns - Figure 7a). Temporary closure is then essential until physiological improvement is displayed by the patient. Available split-skin graft or Integra™ is never applied within the first 48 hours of burn excision in the patient housed on the ICU. Any physiological deterioration in this time tends to result in the use of inotropes, which shut down the peripheral circulation. This can result in loss of graft and Integra™ and conversion of skin graft donor sites to full-thickness injuries (not only increasing the size of the wound needing grafting, but reducing donor site availability). Following burn excision, therefore, Biobrane™ is applied to the underlying fat as a temporising dressing (Figures 7b & 7c). This usually stays in situ for 3 - 6 days until definitive closure can be afforded (most often with Integra although the back is always grafted).

**Discussion**

In order to justify its expense and operative placement under general anaesthesia, the use of Biobrane™ for the definitive management of spontaneously healing burns has to display advantages over alternative, less invasive dressing regimes. The two main parameters are the degree of post-operative pain and the length of stay in hospital. A third parameter might be the time to return to work. Pain is extremely
important; it dictates how much narcotic analgesic will be required. This together with the need for physiotherapy and occupational therapy will dictate how quickly and how completely the patient will regain function. Obviously, the sooner a patient can cope with their injury by themselves, the sooner they can be discharged from hospital and the sooner they will return to work.

In 2007, we surveyed 60 patients, with an average age of 42.4 years (range 16 to 82), who had received Biobrane™ for definitive treatment of superficial partial thickness to mid-dermal burns. We were interested in their pain scores, measured by Visual Analogue Scale, before and after the application of Biobrane™. Overall, the background pain score before application was 6.4, rising with examination. Most also remembered feeling ‘groggy’ due to opiates. Post-Biobrane™ application, the pain scores fell to an average of 3.8. This fall in pain score is despite 8 patients of the 60 surveyed who complained that pain increased after Biobrane™ application (presumably due to the aggression of their in-theatre debridement). The average time to return to work was 4.5 weeks, longest in those with hand burns and working in hot environments (foundries, kitchens etc). Figures from the Burns Round-Table (comparative data for all Burns Services in Australia and New Zealand) show that we enjoy the shortest lengths of stay of any unit. The appropriate use of Biobrane™ in superficial partial thickness and mid-dermal burns has been pivotal in enabling earlier discharge. Our general experience with Biobrane™ use tallies well with the experience of its early evaluators in several applications.

Retrospective analysis also shows that Biobrane™ becomes progressively more effective in reducing length of stay as the burn size increases (Table 1).

**Table 1**
A small number of patients skewed the data, spending far longer in hospital than their group peers. Further analysis of demography and burn site revealed that patients stayed in hospital longer if they:

- were elderly
- lived alone or were homeless
- came from rural locations
- had hand burns requiring therapy or burns to other 'special areas' (feet, genitalia, breasts, buttocks) making early discharge impossible.

Those patients from 2002 (my first year as a burns specialist) stayed slightly longer than subsequent years; an obvious learning curve. Readers might question such aggressive management of small (<10% TBSA) burns by this method and why this particular course is favoured. I am the sole burns surgeon in a State unit with 8 beds and 20fte nurses and responsible for a catchment area of 2.4m square kilometres. In 2008, we accepted 456 admissions and the unit managed over 2,500 outpatient visits. Without the expeditious application of Biobrane™, this workload could not be managed without greatly increasing the in- and out-patient dressing burden on the nurses and increasing the length of stay. Additional support for this aggressive approach is provided by Phillips et al (1989)². Their paper reported experience on 851 patients and identified two potential areas of Biobrane™ failure; namely inaccurate assessment of burn depth and application of Biobrane™ over pre-treated wounds. Removal of all non-viable tissue and meticulous cleaning of the burn bed to stimulate exudation eradicates both these concerns. The infection rate (5.8%) reported in that paper is tenfold greater than our own.

The need for meticulous preparation of superficial burns before the application of Biobrane™ is not a new concept. Demling (1995) ³ elucidated most of the factors I find important, although he makes no reference to whether his “aggressive debridement” required a general anaesthetic. He also highlights that Biobrane™ will not adhere in deeper wound environments, using the failure of Biobrane™ in such cases as a diagnostic test similar to my ‘trial of life’ application.

I have been asked on several occasions why I apply Biobrane™ rather than cadaver allograft as a temporising dressing after excision of major burn injury. The two cadaver banks available to Adelaide are based in Melbourne (Victoria, Australia) and Auckland (New Zealand). Both have faced great difficulty in generating and maintaining stock, and more often than not, requests for large volumes of allograft are not met with supply, due to stock shortage or exhaustion. Cadaver allograft from both sources is expensive and of variable quality. It has a limited shelf life and the Therapeutics Goods Administration (TGA) will not allow its storage in Adelaide if it is not used immediately. Stock which has displayed ‘acceptable’ contamination with staphylococcus aureus or other potential pathogens is sometimes provided. Distance (Melbourne-Adelaide 732km, Auckland-Adelaide 3750km) and delay (both banks are at least one aeroplane flight away) compound the supply problem. Many of these issues were raised by Purdue and colleagues during their prospective study in 1985-1987 ⁴. This multi-centre study failed to show any significant difference between cadaver allograft and Biobrane™ for this application whilst awaiting definitive autografting.

Even the use of Biobrane™ to hold meshed autograft has historical precedent with previous authors having similar success when comparing Biobrane™ to a range of biological materials including cadaver allograft and porcine xenograft.⁵⁻⁶

The success of early authors (particularly the Hansboroughs, John ⁶ and Wendy ⁷) in making Biobrane™ work on donor sites has been impossible to emulate. I thought that fastidious donor site preparation with adrenaline tumescence (so that the donor site does not bleed but merely exudes serum) would guarantee success. However, the Biobrane™ seemed consistently to become ‘cemented’ to the donor site with sanguinous clot. Its detachment was almost impossible without anaesthetic and removal disturbed re-epithelialisation. Patients also complained that they found its presence on donor sites to be extremely uncomfortable and outer dressing changes excruciating. In addition, the quality of re-epithelialisation
appears more fragile during re-harvesting than my usual hydrocolloid method. These findings were considerably disappointing since success would certainly have been advantageous in major burn injury (reducing dressing time, allowing continuation of the temporising Biobrane™ sheets over adjacent donor areas and retaining cultured keratinocyte suspensions for expedition of donor site re-epithelialisation etc). Since I have had great success with hydrocolloids in donor site management, Biobrane™ was discontinued for this application.

Similarly, the use of Biobrane™ on the face is difficult and disappointing. The elasticity which confers excellent appositional advantage on convex surfaces such as the limbs and trunk, causes the material to ‘tent’ over concavities such as the orbits, naso-maxillary and nasolabial folds. The need to staple or suture the material into these creases removed any advantage over soft paraffin face care. We enjoyed great success with Transcyte™ in face management, especially in the Intensive Care setting, finding face care to be its only success with Transcyte™ in face management, especially in intubated patients.

The adherence of Biobrane™ is probably due to the conversion of fibrinogen (in the burn exudate) to monomeric fibrin following its exposure to Biobrane’s™ ‘foreign’ fragments of porcine collagen. The material is then held by the fine, fibrous ‘clot’. This explains its failure to adhere to deeper (non-exuding) burn wounds. The same process occurs when Biobrane™ is applied to a bleeding wound bed, except the result is a dense blood clot which makes detachment problematical. The fibrovascular ingrowth, which occurs when Biobrane™ is applied to excised burn beds following deep burn debridement, can be disastrous if ignored. The nylon scaffold is not biodegradable and, once ingrown, requires surgical removal (often setting the wound back). Although I have several indications for applying Biobrane™ to a deep wound bed (graft holding and temporisation of the burn wound in the big burn), strict protocols ensure its timely and easy removal in these situations.

Problems with Biobrane™ are more frequently a fault of technique rather than material. Biobrane™ is quite ubiquitous when one remembers what it consists of and realises what can be expected of it. Like all burn treatments, it is not a panacea; it is a tool which has specific uses. It has disadvantages also. In Australia, it has only very recently been granted Therapeutic Goods Administration (TGA) approval for use, previously restricting those who could use it; requiring annual submission of cases in whom it had been used, plus a letter from the hospital ethics committee supporting its continued use. It is expensive relative to other dressing materials for spontaneously healing burns (especially the gloves). The meticulous wound preparation necessary for success requires a general anaesthetic or Biobrane™ loss can be expected. Regulation has made it a highly specialist dressing, so discharge of patients treated with Biobrane™ to rural areas is usually delayed. It cannot be applied on delayed presentation burns. Considerable experience is necessary for use in other roles (ie graft holding) but experience has been difficult to acquire previously because of regulation.

### Standard nursing management

A robust nursing protocol must exist to monitor the progression of the product and direct nursing intervention, especially when Biobrane™ is introduced as a new product into a Burns Service or used on out-lying patients from the Burns Unit (e.g. ICU). Biobrane™ gloves are encased in a ‘boxing glove’ bandage and left intact for 3 days. Biobrane™ applied for any indication except dermabrasion (where the risk of surface contamination is minimal) is inspected daily for signs of infection or non-adherence. Any air or fluid collections are removed. If Acticoat™ is used as the outer dressing, this is lifted, the Biobrane™ inspected and the Acticoat™ placed back in position, only being replaced as per normal use. Once exudate ceases, a dry dressing can be applied. One of the main challenges is to prevent the inadvertent early removal of the Biobrane™ before it has been allowed to fulfil its function. If Hypafix™ or staples are used to fix the material, they should not be removed prior to the product being well adhered. Trimming of Biobrane™ occurs as the material becomes dry and opaque indicating healed burn underneath.

If Biobrane™ does not adhere, but there is a clean wound underneath, the nurses are instructed not to remove the product. In the case of a localised non adherent area associated with purulence, only the local area should be de-roofed. Swabs from the underlying wound should be taken and sent for microbial culture, the wound cleaned and Acticoat™ applied. In the case of widespread non-adherence associated with purulence, an urgent medical review is sought. Normal practice in this situation is removal of all loose Biobrane™, wound swabs taken for culture, the wound cleaned and Acticoat™ applied.

### Table 1. Hospital stay with increasing burn size after Biobrane application

<table>
<thead>
<tr>
<th>Burn range (sample number)</th>
<th>1 - 4% (n=334)</th>
<th>5 - 9% (n=72)</th>
<th>10 - 19% (n=42)</th>
<th>20 - 29% (n=13)</th>
<th>30 - 39% (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average TBSA</td>
<td>2.52</td>
<td>7.13</td>
<td>12.43</td>
<td>22.54</td>
<td>33.63</td>
</tr>
<tr>
<td>Length of stay</td>
<td>4.73</td>
<td>8.07</td>
<td>9.69</td>
<td>11.85</td>
<td>13.13</td>
</tr>
<tr>
<td>Days/TBSA</td>
<td>1.88</td>
<td>1.13</td>
<td>0.78</td>
<td>0.53</td>
<td>0.39</td>
</tr>
</tbody>
</table>

**Greenwood JE et al.**
Conclusion

Biobrane™ is ubiquitous and used in my practice for a range of applications. It is relatively inexpensive, easy to store, apply and fix and reliable when used according to guidelines. In the definitive management of burns expected to heal spontaneously, failure is very uncommon. Although experience is necessary for the other applications mentioned, use is usually rewarded with a course and result at least comparable, and usually better, than any alternative (Figure 7e). It is important, however, to know its limitations. Recently, Aubrey Woodroof (the inventor of Biobrane™), has developed an Advanced Wound Bioengineered Alternative Tissue (AWBAT™) 11. This material employs a similar structure to Biobrane™ except the nylon filaments are finer (15/2 denier on standard AWBAT™), the pores are more regular and frequent with uninterrupted nylon mesh flooring them and the porcine collagen peptides are not cross-linked (providing less steric hindrance in their interaction with burn wound exudate) thus expediting adherence. I look forward to comparing this new material with Biobrane™.

This paper was first published in ePlasty on June 26th 2009; 9:243-1255.

References

6. Hansborough JE. Use of Biobrane for extensive posterior donor site wounds. JBCR May/June 1995:16(3) Supplement;335-336.

Product news

“PRONTOSAN®”

Prontosan® a surfactant containing wound irrigation and cleansing Solution and Gel. Prontosan® has been specifically designed for use on Chronic and Acute wounds.

It has two important ingredients that:

• Reduce Chronic Inflammation
• Provide improved pain control
• Absorption of wound odours
• Reduce Bioburden

With fast application and no need to use alternative solution, Prontosan® now offers you an effective tool for your wound management practice.

The New Direction of Wound Cleansing in Australia: Prontosan® Solution

Applied by rinsing direct out of the bottle and also in gauze application, Prontosan® includes the unique ingredients of Betaine (Surfactant) and Polyhexanide (or PHMB; preservative known for its’ anti-microbial properties), which physically penetrate wound layers that house exudate, slough and biofilm, whilst still being gentle on the skin.

Prontosan® Solution for Optimal Wound Bed Preparation

Advantages of Using Prontosan®

<table>
<thead>
<tr>
<th>Advantage</th>
<th>Prontosan®</th>
<th>Saline</th>
<th>Water</th>
<th>Antiseptic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction in bioburden</td>
<td>✔</td>
<td>✗</td>
<td>✗</td>
<td>✔</td>
</tr>
<tr>
<td>Safe for long term use</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✗</td>
</tr>
<tr>
<td>No inhibition of granulation tissue</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✗</td>
</tr>
<tr>
<td>Clinical evidence in reduction of pain and odour</td>
<td>✔</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>Can be used up to 8 weeks after opening - cost effective</td>
<td>✔</td>
<td>✗</td>
<td>N/A</td>
<td>✗</td>
</tr>
<tr>
<td>Clinical evidence in reduction of infection rates</td>
<td>✔</td>
<td>✗</td>
<td>✗</td>
<td>✔</td>
</tr>
<tr>
<td>Clinical evidence in improved healing times</td>
<td>✔</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
</tbody>
</table>

Sales Contact: Stuart Riley, 0409 399 629
B. Braun Australia – 1800 251 705